Anterior vs SamaCare
Two Prior Authorization vendors, side by side. Facts from public sources; judgments are ours.
At a glance
Derived from public facts · a rough scale, not a ranking
| Anterior | SamaCare | |
|---|---|---|
| Pricing model | Enterprise contract (custom) · Payer enterprise deals only | Free to providers (funded by payers/pharma) · Pharma funds premium services and data |
| Speed to go live | Embedded team, deep payer integration | Web portal, no IT project required |
| Automation model | AI copilot · Clinician-in-loop utilization review | Software platform · Unified PA portal, AI touchless tier |
| Built for | Payers | Small practices, Mid-size groups |
| Security posture | HIPAA | SOC 2 Type I, HIPAA |
| Company maturity | 3 yrs (est. 2023) | 8 yrs (est. 2018) |
| Financial backing | $64M · Series B | $33M+ · Series B |
| Named customers | 1 named | None public |
| Published results | Specific numbers public | No public numbers |
| Documented integrations | 1 listed | 4 listed |
| Third-party validation | KLAS / analyst cited | None found |
Bottom line
- Pick Anterior if you are a health plan that wants clinician-supervised AI to cut prior auth review time while keeping final decisions with your own staff.
- Pick SamaCare if you are a specialty practice buried in medical-benefit prior auths and want one free web portal replacing faxes and payer portals today.
Anterior
Clinician-led AI for health plan clinical reviews
- Founded
- 2023
- HQ
- New York, NY
- Stage
- Series B
- Raised
- $64M
What it does
- AI clinical reasoning against payer medical policies
- Prior authorization review with nurse-in-the-loop workflow
- Auto-approval of clean requests, flagging of edge cases
- Embedded clinicians who tune accuracy in production
- Audit trails for every determination
- Five-day average deployment into plan workflows
Where it's strong
- Clinical accuracy of 99.24% in live production was independently validated by KLAS Research.
- Founded and staffed by clinicians, which helps with medical director buy-in inside plans.
- Deploys into existing UM workflows in days rather than the multi-month integrations typical of payer software.
What buyers should weigh
- Sells only to payers, so provider organizations looking for a submission-side tool are not the buyer.
- Young company with a small number of named reference customers, so diligence on scale is warranted.
- State laws increasingly require licensed clinicians to make denial decisions, so buyers must define where AI output stops and human judgment starts.
Named customers
Geisinger Health Plan
Integrations
SamaCare
Prior authorization platform for buy-and-bill specialty drugs
- Founded
- 2018
- HQ
- San Francisco, CA
- Stage
- Series B
- Raised
- $33M+
What it does
- One portal for all medical benefit PA submissions
- AI-assisted form completion and payer requirements
- Status tracking, renewals, and expiration alerts
- Benefit verification and enrollment workflows
- Approval analytics across a 20K-provider network
Where it's strong
- Purpose-built for buy-and-bill drugs, a workflow retail-focused PA tools handle poorly.
- Free for practices because pharma funds it, which removes the budget fight.
- Network data from roughly 20,000 providers improves payer form accuracy and approval odds.
What buyers should weigh
- The pharma-funded model means manufacturers see aggregate data; understand the data terms before signing.
- Scope is medication PA for specialty drugs, not procedures, imaging, or surgical auths.
- Smaller company (Series B) than incumbent networks, so vendor risk is higher than with McKesson or Optum.
Integrations
Compare against the rest of Prior Authorization
Deciding between these two?
First Pass tracks Prior Authorization every week: funding, launches, and what changed since this page was written.